We wonder whether inflammasome activation results in modulation of the mevalonate pathway (especially IPP levels). Reports have described the effect of mevalonate pathway on triggering inflammasome activation but not vice versa. In particular we are interested to look for modulations in this pathway in FMF patients who carry mutations in MEFV gene encoding for pyrin.